Promising Medical Breakthroughs by Premier Biomedical, Inc.
El Paso, Texas, July 29, 2014, Uptick News Wire sat with President and CEO of Premier Biomedical Inc., Mr. William A. Hartman, to get the scoop on their medical miracles that are stretching scientific limits. Based in El Paso Texas., Premier Biomedical Inc. is working closely with the US Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP) in high hopes of creating a brighter future for those that have little hope of seeing that future today.
Dr. Mitchell S.Felder, Chairman of Premier Biomedical’s Scientific Advisory Board, has developed a revolutionary approach to conquering disease by physically removing the pathophysiologic basis of disease ™ from body fluids identified as pico-gram-size (one-trillionth of a gram) disease antigens through the use of antibodies administered, processed, and removed outside the body. The intent of this process is to eliminate dangerous side-effects of disease-fighting drugs.The company has tentatively identified some 19 diseases associated with cerebral spinal fluid for neurological diseases and blood for blood-born diseases.
Premier Biomedical has prioritized their broad-based research and development in order to focus initially on breast cancer, traumatic brain injury (TBI), Alzheimer’s disease, and MS. The company has identified a number of target antigens associated with each of these diseases and is rapidly developing antibodies in the form of drugs to cure these diseases.
In one example, the antigen or life force of breast cancer was identified as CTLA4. Tests were initiated under the Company’s direction in the first quarter of 2014 involving three groups of laboratory mice injected with breast cancer- – a control group that received no remediation, a second group that received chemo in stages to simulate human dosage frequency, and a third group that received only one subsequent dose of Premier Biomedical’s antibody drug. A total of 24 mice were involved in each group of the duplicated study.
In summary, the results of the study were stunning! The control (no remediation) group and the chemo group mice showed large, black cancer lesions at the breast cancer injection site. Moreover, the chemo group had a substantial percentage show cancer metastasis on the heart, lungs, and liver. The third group that received only one anti-life force treatment from Premier Biomedical had no visible cancer. Moreover, a subset of the Premier Biomedical group rejected subsequent attempts to re-inject breast cancer- – that is, the breast cancer died! This successful animal study was peer-reviewed and presented at the American Association for Cancer Research Symposium on April 5-9, 2014 in San Diego. Further tests of this drug are scheduled.
With our recent discovery in our sit down with Premier Biomedical, Inc, Uptick News Wire is putting a “Buy” rating on BIEI at a 6-month target price of $1.50.
BIEI 0.25 +9%
PMCM 0.0019 +12%
EHOS 0.0025 +14%
DMHI 0.0084 +5%
Premier Biomedical, Inc. BIEI
July 24th, 2014
Premier Biomedical, Inc. (OTCBB: “BIEI”) a biopharmaceutical company focused on developing and commercializing innovative treatment therapies for cancer, traumatic brain injury, Alzheimer’s disease, and other afflictions announced today that it is drafting a protocol for the Institutional Review Board overseeing the Company’s clinical trial of Feldetrex™, a revolutionary new pain treatment. The Company anticipates being able to submit the complete protocol in mid-August. A second clinical trial of the Company’s core technology to physically remove the pathophysiologic basis of disease™, will follow.
The Feldetrex™ trial will treat patients suffering from fibromyalgia, MS, and neuropathy. This double-blind study will test the patient population via a Sequential Series of Tests [or via a Cross-Over Test]. The patients will be given one of four treatments: a placebo, Lyrica®, Feldetrex™ or a Lyrica-Feldetrex™ blend. Dr. Roxanna Delgado, part of the US Army-based team administering the clinical trial, will conduct both clinical trials at the William Beaumont Army Medical Center (WBAMC). She will receive the support of the medical experimentation statistical service department at the University of Texas, El Paso, under the auspices of Dr. Robert Kirken, UTEP’s principal investigator. The US Patent Office recently allowed 4 claims for Feldetrex™.
William Hartman, President and CEO of Premier Biomedical stated, “We are looking forward to working with the Army in these trials. We believe that both of our technologies, Feldetrex™ and the removal of the pathophysiologic basis of disease, will be of immense benefit to patients. Given the special situation of our wounded heroes, I am particularly happy that we have the chance to work with the Army to bring some relief to the patriots who are still suffering on our behalf.”
Premier Biomedical also plans to conduct a study on its core technology to physically remove the pathophysiologic basis of disease™. In particular, the Company seeks to demonstrate that it can remove the malevolent molecular compounds that cause clinical depression leading to suicide/homicide ideation. The US Patent Office recently allowed 20 claims covering this basic technology underpinning Premier’s on-going research into new treatments for many of today’s most debilitating diseases.
Mr. Hartman continued, “By removing these compounds from the cerebral spinal fluid of individual soldiers suffering from traumatic brain injury and/or PTSD we are removing the very thing that causes their illnesses. We have arrived at this point because we already successfully removed these same malevolent particles from pooled CSF furnished through the WBAMC Army-based team. This is a revolutionary approach to the problem, and we are very hopeful that this upcoming trial will represent another step forward in the treatment of brain injuries and PTSD.”
This second test will also take place at the WBAMC immediately following the completion of the first clinical study and will be administered by the same Army-based team. The protocol will be drafted for IRB review as the first study progresses.
Here is a list of our TOP 100 Penny Stocks to watch.
Click on the Current Week OR View our Archives.
IDOI 0.0009 +50%
PMCM 0.0018 +12%
APPZ 0.0008 +33%
PWDY 0.0032 +14%
ERFB 0.118 +71%
ENIP 0.0219 +24%
FLXT 0.0597 +26%
DMHI 0.01 +11%